SB 222200, >=98% (HPLC), solid
Application
The pharmacodynamics profile of SB 222200 enables its use as a tool to study physiological and pathophysiological roles of NK-3 receptor in CNS-modulated behaviors.
Biochem/physiol Actions
Non-peptide NK3 tachykinin receptor antagonist.
SB 222200 is a 2-phenyl-4-quinolinecarboxamides and a selective, reversible and competitive antagonist of human NK-3 receptor that effectively crosses the blood-brain barrier. It inhibits the NK-3 receptor-induced miosis or pupil constriction in conscious rabbits.1,2
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
Packaging
10, 50 mg in glass bottle
| Colour | light yellow |
|---|---|
| Quality Level | 100 |
| InChI key | MQNYRKWJSMQECI-QFIPXVFZSA-N |
| InChI | 1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1 |
| Manufacturer | SIGMA-ALDRICH |
| Form | solid |
| Assay | ≥98% (HPLC) |
There are no downloads for this product.
